| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 15, 2025 |
| Accession Number: | 0001213900-25-041997 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
JERUSALEM, May 30th, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the first three months ended March 31, 2025. Three (3) Months of 2025 Financial Summary Revenues for the three months ended March 31, 2025, totaled $586 thousand. The Company's CDMO unit began generating revenues in the second quarter ended June 30, 2024. As disclosed in the Company's Annual
JERUSALEM, May 7, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its annual financial results for the full year 2024. Full year 2024 Financial Summary Revenues for 2024, amounted to $658 thousands, compared to no revenues for 2023. The increase was due to the CDMO starting to generate revenues for the first time in 2024.R&D expenses for 2024, amounted to $5.6 million compared to $5.2
The webinar will explore PC111, a novel monoclonal antibody drug candidate with the potential to transform the treatment landscape for Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). JERUSALEM, Israel, May 1, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and which provides CDMO services through its Scinai Bioservices unit, today announced that it will be hosting a webinar on Wednesday May 7th at, at 11:30 AM EST / 18:30 Israel time. The webinar will address the unmet needs in treating Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic
Scinai files an application for Euro 12 million grant to fund next stage of development Pincell's monoclonal antibody, PC111, is in development for treating Pemphigus, Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)PC111 has already received an Orphan Drug Designation in Pemphigus by the European Medicine's AgencyAn application will be filed with the FDA for Orphan Drug and Breakthrough Designation in Pemphigus, as well as in SJS/TENScinai sees potential for accelerated approval given the severity of these diseases, PC111's innovative, non-immunosuppressive mode of action and the lack of effective alternative treatmentsJERUSALEM, March 27, 2025 /PRNewswire/ -- Scinai Imm
JERUSALEM, Dec. 5, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in the development of inflammation and immunology (I&I) biological products and offering CDMO services through its Scinai Bioservices unit, announced today the appointment of Prof. Michael Schön to its Scientific Advisory Board (SAB). Prof. Michael Schön is a distinguished Professor and Director of the Department of Dermatology, Venereology, and Allergology at the University Medical Center Göttingen. He also serves as Vice D
JERUSALEM, Feb. 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat Halpert as Head of Business Development and Sales. Halpert brings extensive pharmaceutical sales and marketing experience and joins Scinai following 14 years at Novartis, most recently having served as Marketing and Commercial Excellence Lead for cell and gene therapies for Central, Southern and Eastern Europe. Scinai's broad pharmaceutical development experience, along with its end-to-e
SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)
SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)
SC 13D - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)
JERUSALEM, May 30th, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the first three months ended March 31, 2025. Three (3) Months of 2025 Financial Summary Revenues for the three months ended March 31, 2025, totaled $586 thousand. The Company's CDMO unit began generating revenues in the second quarter ended June 30, 2024. As disclosed in the Company's Annual
JERUSALEM, Nov. 22, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today published its financial results for the nine months ended September 30, 2024 and provided a business update. Business Update & Recent Highlights Conversion of EIB Loan into Equity bringing shareholders' equity to $10 million On August 21, 2024, the Company announced that it had closed a Loan Restructuring Agreement, which included an amendment and restatement to the amended Finance Contract wi
JERUSALEM, Aug. 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) (the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it has signed a definitive Loan Restructuring Agreement (the "Restructuring Agreement") with its lender, the European Investment Bank (the "EIB"). The Restructuring Agreement also included an amendment and restatement to the Finance Contract (the "Finance Contract") between the parties. In connection with the transactions, an amount equal to approximately EUR 26.6 million (equal to approxim
EFFECT - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
POS AM - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
20-F - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)